

4-phenylbutyrate therapy
restores the calcification
inhibition potential of ABCC6
missense mutations

Hi'ilani Hopkins

ABCC6

- Active (ATP-dependent) transporter
- Helps to inhibit calcification through pyrophosphate production
- Expressed in the liver, kidney, and intestine
- Localized in the plasma membrane
- Mutations lead to genetic diseases (PXE and GACI)


Pseudoxanthoma Elasticum (PXE)

Human Phenotype


Dermal



Ocular



Vascular




Mouse Phenotype

Abcc6^{-/-} Whiskers



Abcc6^{-/-} Artery





Abcc6^{-/-} eyes (Bruch's membrane)

Hypothesis

- 4-phenylbutyrate (4-PBA)
 - drug used to treat urea cycle disorders
 - also interferes with ER chaperones
- Most ABCC6 mutants have normal transport activity, but abnormal cellular localization, which can be rescued by 4-PBA (Le Saux et al., 2011; Pomozi et al., 2014)
- Because 4-PBA rescues plasma membrane localization of several ABCC6 mutants, we hypothesize that it will also rescue ABCC6's function *i.e.* calcification inhibition


4-PBA interferes with ER chaperones

- Inducing Hsp-70 and Hsp-90
- Inhibiting Hsc-70 and CHIP



Purpose

Can 4-PBA restore plasma membrane localization of various ABCC6 mutants and stop/prevent further calcification?




As an existing drug, 4-PBA could be a feasible way to treat PXE patients.

Methods


- Used an ABCC6 KO mouse strain (mice had no ABCC6 protein)
- Hydrodynamic tail vein injections of a plasmid allowed expression of mutant and normal human ABCC6 in liver
- Cryoinjury of hearts induced cardiac calcification in ABCC6 KO mice
- Immunohistochemistry of livers to verify expression of human ABCC6

The cellular localization of 40% of the mutants can be rescued by 4-PBA treatment *in vivo* (in humanized mouse model)



Pomozi *et al.* 2013, J. Invest. Dermatol.; Le Saux *et al.* 2011, PLoS One


Heart Calcification




My Role in the Project

- These results were submitted for publication in the Journal of Investigative Dermatology
 - Reviewers requested additional data, in particular histology of hearts
- Immunohistochemistry to verify that mouse livers expressed the human ABCC6
- Microscopy imaging

My Role in the Project



My Role in the Project



Conclusion

- 4-PBA is effective for certain mutants (R1314W, Q1347H, S1121W)
 - Can stop and prevent calcification, but cannot reverse existing calcification
- 4-PBA can be used to treat some PXE patients
- The manuscript was resubmitted

(V. Pomozi, C. Brampton, F. Szeri, D. Dedinszki, E. Kozak, K. van de Wetering, H. Hopkins, L. Martin, A. Varadi, and O. Le Saux)

Acknowledgments

A photograph of a mouse, likely a laboratory mouse, seen from the side and slightly from behind. The mouse is light-colored with some darker patches. It is standing on a dark, reflective surface. The background is a warm, orange-yellow gradient, suggesting a light source like a sunset or a warm lamp. The mouse's tail is long and pinkish-red, and its paws are also visible.

Olivier Le Saux, PhD
Viola Pomozi, PhD
Janna Zoll, MS

STEP-UP Program
George Hui, PhD
Fiona Brown

NIH Grant: HL108249